Keir, Holly RLong, Merete BAbo-Leyah, HaniGiam, Yan HuiVadiveloo, ThenmalarPembridge, ThomasHull, Rebecca CDelgado, LiliaBand, MargaretMcLaren-Neil, FionaAdamson, SimonLahnsteiner, EvaGilmour, AmyHughes, ChloeNew, Benjamin JmConnell, DavidDowey, RebeccaTurton, HelenaRichardson, HollianCassidy, DianeCooper, JamieSuntharalingam, JayDiwakar, LavanyaRussell, PeterUnderwood, JonathanHicks, AlexanderDosanjh, Davinder PsSage, BethDhasmana, DeveshSpears, MarkThompson, AA RogerBrightling, ChristopherSmith, AndrewPatel, ManishGeorge, JacobCondliffe, Alison MShoemark, AmeliaMacLennan, GraemeChalmers, James DSTOP-COVID19 Investigators2023-02-152023-02-152022-12-01Keir, H R, Long, M B, Abo-Leyah, H, Giam, Y H, Vadiveloo, T, Pembridge, T, Hull, R C, Delgado, L, Band, M, McLaren-Neil, F, Adamson, S, Lahnsteiner, E, Gilmour, A, Hughes, C, New, B J, Connell, D, Dowey, R, Turton, H, Richardson, H, Cassidy, D, Cooper, J, Suntharalingam, J, Diwakar, L, Russell, P, Underwood, J, Hicks, A, Dosanjh, D P, Sage, B, Dhasmana, D, Spears, M, Thompson, AA R, Brightling, C, Smith, A, Patel, M, George, J, Condliffe, A M, Shoemark, A, MacLennan, G, Chalmers, J D & STOP-COVID19 Investigators 2022, 'Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19 : a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial', The Lancet. Respiratory medicine, vol. 10, no. 12, pp. 1119-1128. https://doi.org/10.1016/S2213-2600(22)00261-22213-2600PubMedCentral: PMC9442496ORCID: /0000-0002-1039-5646/work/188766253ORCID: /0000-0003-3812-7026/work/188766569https://hdl.handle.net/2164/20056Acknowledgments This study was funded by an investigator-initiated research grant from Insmed (Bridgewater, NJ, USA). The authors acknowledge Stephen Senn (Edinburgh, UK) for independent statistical advice and Alex McConnachie (University of Glasgow, Glasgow, UK), Aran Singanayagam (Imperial College, London, UK), Oriol Sibila (Hospital Clínic Barcelona, Barcelona, Spain), and Petra Rauchhaus (University of Dundee, Dundee, UK) for serving as the independent data monitoring committee. The STOP-COVID19 study was designated an urgent public health priority study by the UK National Institute for Health and Care Research. The authors acknowledge the funding and logistical support from the UK National Institute for Health and Care Research.10981900engHumansCOVID-19 Drug TreatmentDouble-Blind MethodSerine ProteasesTreatment OutcomeCathepsin C/antagonists & inhibitorsR Medicine (General)Pulmonary and Respiratory MedicineSupplementary DataDASSupplementary InformationR1Journal article10.1016/S2213-2600(22)00261-2https://www.scopus.com/pages/publications/85142783776